drugset / Trial / NCT00259831

Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

NCT00259831 ↗

Phase 3 Completed 500 enrolled CV Technologies Capital Health, Canada · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care facilities. It is hypothesized that the use of CVT-E002 will effectively reduce the incidence, severity and duration of upper respiratory infections among the participants when compared to placebo.

Timeline

Start
2005-12
Primary completion
2006-06
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CVT-E002 Other / unclassified 400 mg Oral